Thomas F. Pajak

31.8k total citations · 12 hit papers
165 papers, 19.6k citations indexed

About

Thomas F. Pajak is a scholar working on Otorhinolaryngology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Thomas F. Pajak has authored 165 papers receiving a total of 19.6k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Otorhinolaryngology, 61 papers in Pulmonary and Respiratory Medicine and 55 papers in Oncology. Recurrent topics in Thomas F. Pajak's work include Head and Neck Cancer Studies (63 papers), Lymphoma Diagnosis and Treatment (29 papers) and Lung Cancer Treatments and Mutations (28 papers). Thomas F. Pajak is often cited by papers focused on Head and Neck Cancer Studies (63 papers), Lymphoma Diagnosis and Treatment (29 papers) and Lung Cancer Treatments and Mutations (28 papers). Thomas F. Pajak collaborates with scholars based in United States, Puerto Rico and Canada. Thomas F. Pajak's co-authors include Jay S. Cooper, Arlene A. Forastiere, John F. Ensley, Karen K. Fu, Andy Trotti, John A. Ridge, Moshe Maor, Helmuth Goepfert, Víctor A. Marcial and Randal S. Weber and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Thomas F. Pajak

161 papers receiving 18.9k citations

Hit Papers

Postoperative Concurrent Radiotherapy and Chemot... 1987 2026 2000 2013 2004 2003 2005 1998 2000 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
    2004 2.3k citations Jay S. Cooper, Thomas F. Pajak et al. profile →
  2. Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
    2003 2.3k citations Arlene A. Forastiere, Helmuth Goepfert et al. profile →
  3. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
    2005 1.2k citations Jay S. Cooper, Thomas F. Pajak et al. Head & Neck profile →
  4. Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal Cancer
    1998 997 citations David P. Kelsen, Robert J. Ginsberg et al. profile →
  5. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
    2000 983 citations Karen K. Fu, Thomas F. Pajak et al. International Journal of Radiation Oncology*Biology*Physics profile →
  6. Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
    2012 835 citations Arlene A. Forastiere, Qiang Zhang et al. Journal of Clinical Oncology profile →
  7. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy
    2002 799 citations Bruce D. Minsky, Thomas F. Pajak et al. Journal of Clinical Oncology profile →
  8. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
    1996 754 citations Thomas F. Pajak, Marvin Rotman et al. Journal of Clinical Oncology profile →
  9. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis
    2006 752 citations Kian Ang, Thomas F. Pajak et al. profile →
  10. Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02
    2003 526 citations Gerald E. Hanks, Thomas F. Pajak et al. Journal of Clinical Oncology profile →
  11. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy report by the radiation therapy oncology group
    1987 474 citations Thomas F. Pajak, Philip Rubin et al. Cancer profile →
  12. Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck
    2012 385 citations Jay S. Cooper, Qiang Zhang et al. International Journal of Radiation Oncology*Biology*Physics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas F. Pajak United States 57 9.7k 9.6k 9.4k 6.1k 1.8k 165 19.6k
Jay S. Cooper United States 50 13.2k 1.4× 12.6k 1.3× 10.0k 1.1× 6.8k 1.1× 1.4k 0.8× 154 22.7k
Andy Trotti United States 51 9.5k 1.0× 6.3k 0.7× 7.0k 0.7× 5.9k 1.0× 1.4k 0.8× 143 16.6k
Jacques Bernier Switzerland 39 6.4k 0.7× 4.9k 0.5× 6.7k 0.7× 3.6k 0.6× 2.2k 1.3× 112 13.4k
Merrill S. Kies United States 57 5.7k 0.6× 5.2k 0.5× 5.3k 0.6× 7.3k 1.2× 605 0.3× 178 14.6k
Lester J. Peters United States 56 4.4k 0.4× 3.7k 0.4× 4.0k 0.4× 4.1k 0.7× 1.9k 1.1× 181 12.2k
John A. Ridge United States 48 9.9k 1.0× 6.8k 0.7× 4.6k 0.5× 5.7k 0.9× 519 0.3× 207 15.2k
Arlene A. Forastiere United States 68 16.0k 1.6× 13.6k 1.4× 11.2k 1.2× 10.8k 1.8× 583 0.3× 269 28.8k
Mitchell Machtay United States 56 5.4k 0.6× 4.4k 0.5× 7.9k 0.8× 4.1k 0.7× 2.6k 1.5× 299 14.3k
John F. Ensley United States 41 9.9k 1.0× 6.7k 0.7× 4.8k 0.5× 5.6k 0.9× 401 0.2× 125 14.2k
J. Giralt Spain 29 5.7k 0.6× 4.3k 0.4× 4.6k 0.5× 5.3k 0.9× 805 0.5× 118 11.7k

Countries citing papers authored by Thomas F. Pajak

Since Specialization
Citations

This map shows the geographic impact of Thomas F. Pajak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas F. Pajak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas F. Pajak more than expected).

Fields of papers citing papers by Thomas F. Pajak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas F. Pajak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas F. Pajak. The network helps show where Thomas F. Pajak may publish in the future.

Co-authorship network of co-authors of Thomas F. Pajak

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas F. Pajak. A scholar is included among the top collaborators of Thomas F. Pajak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas F. Pajak. Thomas F. Pajak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cooper, Jay S., Qiang Zhang, Thomas F. Pajak, et al.. (2012). Long-term Follow-up of the RTOG 9501/Intergroup Phase III Trial: Postoperative Concurrent Radiation Therapy and Chemotherapy in High-Risk Squamous Cell Carcinoma of the Head and Neck. International Journal of Radiation Oncology*Biology*Physics. 84(5). 1198–1205. 385 indexed citations breakdown →
2.
Minsky, Bruce D., Thomas F. Pajak, Robert J. Ginsberg, et al.. (2002). INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy. Journal of Clinical Oncology. 20(5). 1167–1174. 799 indexed citations breakdown →
3.
Fu, Karen K., Thomas F. Pajak, Andy Trotti, et al.. (2000). A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. International Journal of Radiation Oncology*Biology*Physics. 48(1). 7–16. 983 indexed citations breakdown →
4.
Wolf, Gregory T., Arlene A. Forastiere, Kian Ang, et al.. (1999). Workshop report: Organ preservation strategies in advanced head and neck cancer—Current status and future directions. Head & Neck. 21(8). 689–693. 29 indexed citations
5.
Minsky, Bruce D., Donna Neuberg, David P. Kelsen, et al.. (1999). Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. International Journal of Radiation Oncology*Biology*Physics. 43(3). 517–523. 109 indexed citations
6.
Grignon, David J., Thomas F. Pajak, M.V. Pilepich, et al.. (1997). 1007 The need for central pathology tumor grading in prostate cancer using radiation therapy oncology group(RTOG) 8531. International Journal of Radiation Oncology*Biology*Physics. 39(2). 219–219. 6 indexed citations
7.
Fu, Karen K., Jay S. Cooper, Víctor A. Marcial, et al.. (1996). Evolution of the radiation therapy oncology group clinical trials for head and neck cancer. International Journal of Radiation Oncology*Biology*Physics. 35(3). 425–438. 40 indexed citations
8.
Cox, James D., Thomas F. Pajak, Sucha O. Asbell, et al.. (1993). Interruptions of high-dose radiation therapy decrease longterm survival of favorable patients with unresectable nonsmall cell carcinoma of the lung: analysis of 1244 cases from 3 radiation therapy oncology group (RTOG) trials. International Journal of Radiation Oncology*Biology*Physics. 27(3). 493–498. 164 indexed citations
9.
Lanciano, Rachelle, Thomas F. Pajak, Karen Martz, & Gerald E. Hanks. (1993). The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: A patterns-of-care study. International Journal of Radiation Oncology*Biology*Physics. 25(3). 391–397. 275 indexed citations
10.
Pajak, Thomas F., Víctor A. Marcial, John T. Fazekas, et al.. (1991). Elapsed treatment days—A critical item for radiotherapy quality control review in head and neck trials: RTOG report. International Journal of Radiation Oncology*Biology*Physics. 20(1). 13–20. 138 indexed citations
11.
Tupchong, Leslie, D Phil, Charles Scott, et al.. (1991). Randomized study of preoperative versus postoperative radiation therapy in advanced head and neck carcinoma: Long-term follow-up of RTOG study 73-03. International Journal of Radiation Oncology*Biology*Physics. 20(1). 21–28. 173 indexed citations
12.
Diener‐West, Marie, Thomas F. Pajak, Madeline Bauer, & James D. Cox. (1991). Randomized Dose-Searching Phase ILE/II Trials of Fractionation in Radiation Therapy for Cancer. JNCI Journal of the National Cancer Institute. 83(15). 1065–1071. 15 indexed citations
13.
Cooper, Jay S., Thomas F. Pajak, Philip Rubin, et al.. (1989). Second malignancies in patients who have head and neck cancer: Incidence, effect on survival and implications based on the RTOG experience. International Journal of Radiation Oncology*Biology*Physics. 17(3). 449–456. 307 indexed citations
14.
Halsey, Joanne, et al.. (1987). Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.. PubMed. 47(1). 319–22. 55 indexed citations
15.
Pajak, Thomas F., Frank R. Hendrickson, James S. Nelson, et al.. (1985). Fast neutrons and misonidazole for malignant astrocytomas. International Journal of Radiation Oncology*Biology*Physics. 11(4). 679–686. 15 indexed citations
16.
Pilepich, Miljenko V., Thomas F. Pajak, Sucha O. Asbell, et al.. (1983). Preliminary report on phase III RTOG studies of extended-field irradiation in carcinoma of the prostate. American Journal of Clinical Oncology. 6(4). 485–492. 15 indexed citations
17.
Danoff, Barbara F., Robert L. Goodman, John H. Glick, Daniel G. Haller, & Thomas F. Pajak. (1983). The effect of adjuvant chemotherapy on cosmesis and complications in patients with breast cancer treated by definitive irradiation. International Journal of Radiation Oncology*Biology*Physics. 9(11). 1625–1630. 98 indexed citations
18.
Cooper, M. Robert, Thomas F. Pajak, Nis I. Nissen, et al.. (1982). Effect of the methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease. Cancer. 49(11). 2226–2230. 5 indexed citations
19.
20.
Hayes, Donald M., Thomas F. Pajak, Vishram B. Rege, et al.. (1979). Combination chemotherapy for non‐Hodgkin lymphomas: A ten year follow‐up study. Medical and Pediatric Oncology. 6(1). 23–38. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jay S. Cooper Breakdown of academic impact, for papers by Andy Trotti Breakdown of academic impact, for papers by Jacques Bernier Breakdown of academic impact, for papers by Merrill S. Kies Breakdown of academic impact, for papers by Lester J. Peters Breakdown of academic impact, for papers by John A. Ridge Breakdown of academic impact, for papers by Arlene A. Forastiere Breakdown of academic impact, for papers by Mitchell Machtay Breakdown of academic impact, for papers by John F. Ensley Breakdown of academic impact, for papers by J. Giralt
Rankless by CCL
2026